AbCellera Biologics (ABCL) Other Operating Expenses: 2019-2024
Historic Other Operating Expenses for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $91.1 million.
- AbCellera Biologics' Other Operating Expenses fell 55.90% to $6.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $25.7 million, marking a year-over-year decrease of 73.41%. This contributed to the annual value of $91.1 million for FY2024, which is 253.41% up from last year.
- According to the latest figures from FY2024, AbCellera Biologics' Other Operating Expenses is $91.1 million, which was up 253.41% from $25.8 million recorded in FY2023.
- Over the past 5 years, AbCellera Biologics' Other Operating Expenses peaked at $115.1 million during FY2020, and registered a low of $25.8 million during FY2023.
- In the last 3 years, AbCellera Biologics' Other Operating Expenses had a median value of $91.1 million in 2024 and averaged $71.1 million.
- Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 1,157.99% in 2020, then slumped by 73.30% in 2023.
- Yearly analysis of 5 years shows AbCellera Biologics' Other Operating Expenses stood at $115.1 million in 2020, then tumbled by 45.71% to $62.5 million in 2021, then skyrocketed by 54.54% to $96.5 million in 2022, then plummeted by 73.30% to $25.8 million in 2023, then soared by 253.41% to $91.1 million in 2024.